For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Singular Genomics Systems Inc (NASDAQ: OMIC) closed at $5.65 down -0.26% from its previous closing price of $5.66. In other words, the price has decreased by -$0.26 from its previous closing price. On the day, 0.89 million shares were traded. OMIC stock price reached its highest trading level at $5.65 during the session, while it also had its lowest trading level at $5.52.
Ratios:
For a deeper understanding of Singular Genomics Systems Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.04 and its Current Ratio is at 8.77. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.47.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on August 17, 2022, Downgraded its rating to Neutral and sets its target price to $4.50 from $10 previously.
On August 10, 2022, Goldman Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $3.50.
BofA Securities Downgraded its Buy to Underperform on August 10, 2022, while the target price for the stock was maintained at $3.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 17 ’23 when Spaventa Andrew bought 75,000 shares for $0.42 per share. The transaction valued at 31,755 led to the insider holds 4,061,206 shares of the business.
Spaventa Andrew bought 43,468 shares of OMIC for $17,857 on Nov 16 ’23. The Chief Executive Officer now owns 3,986,206 shares after completing the transaction at $0.41 per share. On Nov 16 ’23, another insider, Glezer Eli N., who serves as the Chief Scientific Officer of the company, bought 200,000 shares for $0.43 each. As a result, the insider paid 85,640 and bolstered with 4,570,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OMIC now has a Market Capitalization of 14100649 and an Enterprise Value of -43560328. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.19 while its Price-to-Book (P/B) ratio in mrq is 0.10. Its current Enterprise Value per Revenue stands at -15.997 whereas that against EBITDA is 0.464.
Stock Price History:
Over the past 52 weeks, OMIC has reached a high of $19.80, while it has fallen to a 52-week low of $5.34. The 50-Day Moving Average of the stock is -23.22%, while the 200-Day Moving Average is calculated to be -52.15%.
Shares Statistics:
For the past three months, OMIC has traded an average of 7.36K shares per day and 111060 over the past ten days. A total of 2.46M shares are outstanding, with a floating share count of 1.49M. Insiders hold about 40.40% of the company’s shares, while institutions hold 20.38% stake in the company. Shares short for OMIC as of 1723680000 were 13959 with a Short Ratio of 1.56, compared to 1721001600 on 12421. Therefore, it implies a Short% of Shares Outstanding of 13959 and a Short% of Float of 0.69.
